Yale United Way 2019: Help Today. Hope for Tomorrow.

The Yale Microbial Sciences Institute, in partnership with the Departments of Cellular and Molecular Physiology, Genetics, Immunobiology, and Microbial Pathogenesis at Yale School of Medicine, seeks applicants for an assistant professor tenure track faculty position at the interface of microbiology, health, and disease.

Professor Craig Roy has been appointed the new director of the Combined Program in the Biological and Biomedical Sciences (BBS), effective September 1, 2019.

Congratulations to Eduardo Groisman, who has received the 2019 Yale Postdoctoral Mentoring Award! The prize recognizes faculty who best exemplify the role of a mentor and provide exceptional mentoring to current postdoctoral scholars.

Cesar De Leon and Rodolfo Urbano have been selected as Howard Hughes Medical Institute (HHMI) Hanna Gray Fellows. They join 13 other outstanding early career scientists from around the country who were awarded this honor.

Andrew Goodman has been named to head the Microbial Sciences Institute (MSI) at Yale’s West Campus, which focuses on the inner workings of microbes and their interaction with the environment.

Andrew Goodman, PhD, recently named C.N.H. Long Professor of Microbial Pathogenesis, focuses his research on the gut microbiome—the collection of bacteria, mostly in the gastrointestinal tract, that every person acquires after birth.

Yale researchers identified human gut microbes that metabolize over 150 therapeutic drugs, a finding that highlights the role bacteria play in determining how well individuals respond to medications, they report June 3 in the journal Nature.

A Yale-led team has discovered yet another molecular trick HIV uses to survive immune system attacks, a finding that may influence efforts to develop an effective vaccine against HIV/AIDS.

People sometimes suffer toxic side effects from drugs that help many others. Yale scientists have identified a surprising explanation — the gut microbiome. The research, published Feb. 8 in the journal Science, describes how bacteria in the gut can transform three drugs into harmful compounds. “If we can understand the microbiome’s contributions to drug metabolism, we can decide which drugs to give to patients or even alter the microbiome so patients have a better response,” said co-lead author Michael Zimmermann, postdoctoral fellow in the lab of senior author Andrew Goodman in the Department of Microbial Pathogenesis and the Microbial Sciences Institute.